- Clinical leader brings deep expertise in clinical development, medical and regulatory affairs
Newton, MA, June 2, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells today announced the appointment of Niti Goel, M.D., as Chief Medical Officer.
“Niti is a highly regarded drug developer and clinician, and her experience in autoimmune diseases will be instrumental to Abcuro as we advance our lead drug candidate, ABC008, into clinical development for inclusion body myositis,” said David de Graaf, Ph.D., Chief Executive Officer of Abcuro. “Her depth of expertise is also a tremendous asset as we build a robust and innovative pipeline focused on autoimmune and inflammatory diseases.”
Dr. Goel is a board-certified rheumatologist with 25 years of academic, clinical development, and medical affairs experience. She has extensive expertise in clinical trial design and has had successful global regulatory interactions for biologics, cellular therapies, and small molecules. She previously served as Chief Medical Officer at Kezar Life Sciences as well as held roles of increasing responsibility at IQVIA, the Human Data Science Company, Array BioPharma, Inc., UCB Pharma, and Procter & Gamble Pharmaceuticals.
Dr. Goel is also currently an adjunct Assistant Professor of Medicine at Duke University School of Medicine in the Division of Rheumatology. She received a B.S. degree from Pennsylvania State University and her M.D. degree from Jefferson Medical College of Thomas Jefferson University. She completed her internal medicine and rheumatology training at Duke University Medical Center.
“Abcuro’s ability to precisely target the immune cells that play a pivotal role in autoimmune diseases and cancer has the potential to deliver transformative therapeutic options to patients,” said Dr. Goel. “I’m excited to join Abcuro at this important time and help realize the potential of this approach.”
Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of T and NK cells that express KLRG1 (killer cell lectin like receptor G1). In certain autoimmune diseases, KLRG1-expressing T cells are the source of chronic tissue damage. In oncology, tumor cells that express E- or N- cadherin inhibit anti-tumor activity of T and NK cells via their KLRG1 receptor, therefore acting as an immune checkpoint inhibitory receptor. KLRG1 was identified as a compelling target with relevance to disease biology through Abcuro’s powerful use of patient clinical data and patient tissue transcriptome analyses derived from discrete, pathological immune cell subpopulations. For more information, visit abcuro.com.